Drugs / Universal STAR-T Cell
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07714798 | Jul 2026 → Jul 2027 expected | generalized myasthenia gravis | Daishi Tian | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07599280 | May 2026 → May 2027 expected | thrombocytopenia due to immune destruction | Jian Zhu | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Universal STAR-T Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07599280 ↗ |
| Modality | Cell therapy | “universal STAR-T cells” NCT07599280 ↗ |
| Route | Intravenous | “administered as a single intravenous infusion.” NCT07714798 ↗ |